Aliases:This biomarker is also known as:
- Short-chain type dehydrogenase/reductase XH98G2,
- endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- hydroxysteroid (17-beta) dehydrogenase 10,
- mitochondrial ribonuclease P protein 2,
- 17-beta-hydroxysteroid dehydrogenase 10,
- hydroxyacyl-Coenzyme A dehydrogenase, type II, hydroxyacyl-Coenzyme A dehydrogenase, type II,
- short chain L-3-hydroxyacyl-CoA dehydrogenase type 2,
- AB-binding alcohol dehydrogenase,
- Endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- Mitochondrial ribonuclease P protein 2,
- mitochondrial RNase P subunit 2,
- short chain type dehydrogenase/reductase XH98G2,
- Type II HADH,
- 17-beta-HSD 10,
- Mitochondrial RNase P protein 2,
- mental retardation, X-linked, syndromic 10,
- short chain dehydrogenase/reductase family 5C, member 1,
- 3-hydroxyacyl-CoA dehydrogenase type-2,
- 3-hydroxy-2-methylbutyryl-CoA dehydrogenase,
- EC 18.104.22.168,EC 22.214.171.124,
- 3-hydroxyacyl-CoA dehydrogenase type II,
- amyloid-beta peptide binding alcohol dehydrogenase,
HSD17B10, hydroxysteroid (17-beta) dehydrogenase 10, is a member of the short-chain dehydrogenase/reductase superfamily. HSD17B10 functions in mitochondrial tRNA maturation and catalyzes the oxidation of a wide variety of fatty acids, alcohols, and steroids. The protein is thought to play a role in the development of Alzheimer's disease. There are several alternatively spliced transcript variants, of which only two have been fully sequenced.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data is available.
HSD17B10 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.